XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent

Authors: Beijk, Marcel AM; Piek, Jan J

Source: Expert Review of Medical Devices, Volume 4, Number 1, January 2007 , pp. 11-21(11)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Drug-eluting stents (DES) have been shown to be safe and significantly reduce clinical events and angiographic restenosis in the percutaneous treatment of coronary artery disease. Currently, three DES have been approved in Europe and Northern America: the sirolimus-eluting stent (SES), the paclitaxel-eluting stent (PES) and the zotarolimus-eluting stent (ZES). Everolimus, an analog of sirolimus, is an immunosuppressive and antiproliferative agent. In three studies, the SPIRIT I, FUTURE I and II, the everolimus-eluting stent has proven to be safe, well-tolerated and has shown very favorable clinical and angiographic results. Compared with earlier-generation DES, the XIENCE V everolimus-eluting coronary stent system (Advanced Cardiovascular Systems Inc., an Abbott Vascular Company, CA, USA) may provide enhanced deliverability, radiopacity with thinner strut filaments and, owing to a durable polymer, sustained drug elution and vascular compatibility.

Keywords: drug-eluting stent; percutaneous coronary intervention; XIENCE V stent

Document Type: Research article

DOI: http://dx.doi.org/10.1586/17434440.4.1.11

Publication date: 2007-01-01

More about this publication?

Expert Review of Medical Devices provides commentary, analysis and debate for all professionals involved in research, development, testing and clinical use of devices.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites